A Dutch based company, “to-BBB”, established to develop drug delivery capabilities across the blood brain barrier, has announced the receipt of EURO1.25M in funding from the European Commission’s 7th Framework Programme (FP7). The award forms part of the “DRUGSFORD” consortium application, entitled “Preclinical development of drugs and drug delivery technology for the treatment of inherited photoreceptor degeneration”, co-ordinated by Dr. FranCois Paquet-Durand. The total value of the consortium award is EURO4,971,428.